Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

被引：27

作者：

Zhao, Wan-Hong ^{[1
]}

Liu, Jie ^{[1
]}

Wang, Bai-Yan ^{[1
]}

Chen, Yin-Xia ^{[1
]}

Cao, Xing-Mei ^{[1
]}

Yang, Yun ^{[1
]}

Zhang, Yi-Lin ^{[1
]}

Wang, Fang-Xia ^{[2
]}

Zhang, Peng-Yu ^{[1
]}

Lei, Bo ^{[1
]}

Gu, Liu-Fang ^{[1
]}

Wang, Jian-Li ^{[1
]}

Yang, Nan ^{[1
]}

Zhang, Ru ^{[1
]}

Zhang, Hui ^{[1
]}

Shen, Ying ^{[1
]}

Bai, Ju ^{[1
]}

Xu, Yan ^{[1
]}

Wang, Xu-Geng ^{[1
]}

Zhang, Rui-Li ^{[1
]}

Wei, Li-Li ^{[1
]}

Li, Zong-Fang ^{[3
]}

Li, Zhen-Zhen ^{[3
]}

Geng, Yan ^{[4
]}

He, Qian ^{[4
]}

Zhuang, Qiu-Chuan ^{[5
]}

Fan, Frank Xiao-Hu ^{[5
]}

He, Ai-Li ^{[1
,3
]}

Zhang, Wang-Gang ^{[1
]}

机构：

[1] Xi An Jiao Tong Univ, Dept Hematol, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[3] Xi An Jiao Tong Univ, Natl Local Joint Engn Res Ctr Biodiagnost & Bioth, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[4] Xi An Jiao Tong Univ, Dept Clin Lab, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China

[5] Nanjing Legend Biotech, Nanjing, Jiangsu, Peoples R China

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-110548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

955

引用

页数：4

共 50 条

[31] Nursing care of patients with relapsed and refractory multiple myeloma treated with B-cell mature antigen-targeted universal chimeric antigen receptor T cells
Dai, Ying
Tang, Fang
Mao, Yanqin
He, Na
Yu, Meimei
Zhang, Mengjiao
Gu, Sumei
Lu, Yin
Shang, Jingjing
Zhu, Xiamin
MEDICINE, 2023, 102 (47) : E36067
[32] Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
Zhu, Feng
Wei, Guoqing
Zhang, Mingming
Zhao, Houli
Wu, Wenjun
Yang, Luxin
Hu, Yongxian
Huang, He
CELL TRANSPLANTATION, 2020, 29
[33] PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Zhang, W.
Zhao, W.
Liu, J.
He, A.
Chen, Y.
Cao, X.
Yang, N.
Wang, B.
Zhang, P.
Zhang, Y.
Wang, F.
Lei, B.
Gu, L.
Yang, Y.
Bai, J.
Zhang, R.
Wang, X.
Ma, X.
Wang, J.
Wang, J.
Wei, L.
Zhang, J.
Zang, X.
Zhuang, Q.
Fan, F. X.
HAEMATOLOGICA, 2017, 102 : 2 - 3
[34] Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma
Banerjee, Rahul
Marsal, Jeffrey
Huang, Chiung-Yu
Lo, Mimi
Kambhampati, Swetha
Kennedy, Vanessa E.
Arora, Shagun
Wolf, Jeffrey L.
Martin, Thomas G.
Wong, Sandy W.
Shah, Nina
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (06): : 477.e1 - 477.e7
[35] Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma
Chen, Dongjian
Wang, Xiaoxiang
Chen, Zhi
Jiang, Songfu
Jiang, Hua
Fu, Weijun
Xiang, Fang
Sun, Xuedong
Du, Juan
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : E478 - E481
[36] Beyond age: safety and efficacy analysis of chimeric antigen receptor T cells against B cell maturation antigen in elderly patients with multiple myeloma
Berrahouane, Rayane
HEMATOLOGIE, 2023, 29 (04): : 219 - 221
[37] Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di, Mengyang
Potnis, Kunal C.
Long, Jessica B.
Isufi, Iris
Foss, Francine
Seropian, Stuart
Gross, Cary P.
Huntington, Scott F.
JNCI CANCER SPECTRUM, 2024, 8 (04)
[38] Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Costa, Luciano J.
Kumar, Shaji K.
Atrash, Shebli
Liedtke, Michaela
Kaur, Gurbakhash
Derman, Benjamin A.
Bergsagel, P. Leif
Mailankody, Sham
McCarthy, Philip L.
Limones, Josiana
Chen, Yanping
Das, Sharmila
Thorpe, Jerill
Cacciatore, Jonathan
Navarro, Garnet
Koegel, Ashley K.
Burgess, Michael R.
Hege, Kristen
Richard, Shambavi
BLOOD, 2022, 140 : 1360 - 1362
[39] Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
Cronk, Robert J.
Zurko, Joanna
Shah, Nirav N.
CANCERS, 2020, 12 (09) : 1 - 15
[40] BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
Fang, Jiamin
Zhou, Fuling
ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1069 - 1083

← 1 2 3 4 5 →